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BSP-GSH binding to TR- CMV was similar to that 
observed in normal CMV would suggest the latter 
hypothesis. 
Clearly the combined effect of the findings from these 
two studies is more than just a better description of 
canalicular non-bile-acid organic anion secretion. Be- 
cause the transport defect has been characterized in a 
mutant animal model, it is only a matter of time before 
the membrane protein involved in the canalicular 
secretion of non-bile-acid organic anions will be iden- 
tified. Radioactive photoaffinity labels are available for 
the detection of glutathione S-conjugate-binding mem- 
brane proteins (12). Once isolated, further studies 
including molecular cloning of this protein will follow. 
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OMEPRAZOLE AND ARYL HYDROCARBON 
HYDROXYLASES: SHOULD WE BE WORRIED? 
Diaz D, Fabre I ,  D a j a t  M, Saint Aubert B, Bories P, 
Michel H, Maurel P. Omeprazole is an aryl 
hydrocarbon-like inducer of human hepatic cytochrome 
P450. Gastroenterology 1990;99:737-747. 
EDITOR’S ABSTRACT 
Diaz and colleagues have carefully studied the ef- 
fects of omeprazole on the expression of cytochrome 
P-450 in primary cultures of human hepatocytes. When 
omeprazole was added to the culture medium in 
varying concentrations, there was an increase in P- 
450IA2 protein and mRNA concentrations, an increase 
in de novo synthesis of P-45OIA2 protein, and an 
increase in microsomal catalytic activities character- 
istic of P-45OIA2 (phenacetin deethylase and acet- 
anilide hydroxylase). Omeprazole treatment also re- 
sulted in an increase in both enzymatic activity char- 
acteristic of P-45OIA1 (ethoxyresorufin deethylase and 
benzpyrene hydroxylase) and concentration of P- 
450IAl mRNA. In contrast, omeprazole appeared to 
have no significant effect on expression of other P-450s 
within the P-45011 or P-450111 families in the hepato- 
cytes. To validate these in uitro observations, liver 
biopsy specimens were obtained from five patients 
before and after a 4-day course of pharmacological 
doses of omeprazole. In each patient, omeprazole 
treatment appeared to result in a two- to eightfold 
increase in P-45OIA2 immunoreactive protein and 
P-45OIA1 and P-45OIA2 enzymatic activities. 
The authors conclude that omeprazole is an inducer 
of P-45OIA2 and probably P-450IA1 in human liver. 
Induction of these enzymes could potentiate the bio- 
activation of carcinogens or the hepatotoxicity of some 
drugs such as acetaminophen. 
COMMENTS 
This is an important article likely to spark consid- 
erable controversy. The data presented and the accom- 
panying editorial (1) appear to raise new concerns about 
the safety of omeprazole (Losec; Merck, Sharp & Dohme, 
Division ofMerck 8z Co., Inc., West Point, PA). This drug 
is the latest addition to the peptic ulcer disease thera- 
peutic arsenal, which accounts for sales well in excess of 
$1 billion annually. As the most potent inhibitor of 
gastric acid secretion clinically available, omeprazole is 
already used widely in the treatment of severe esoph- 
agitis, Zollinger-Ellison syndrome and refractory peptic 
ulcer disease. 
Diaz et al. investigated the effects of omeprazole on 
the regulation of phase I drug metabolizing enzymes 
termed cytochromes P-450 (P-450s). P-450s often play 
critical roles in the metabolism of drugs and other 
xenobiotics found in the environment (2, 3). The P-450 
literature has recently been simplified by the adoption of 
nomenclature that classifies individual P-450 enzymes 
by gene family (designated by roman numerals) (4). 
Three major P-450 families appear to be involved in 
xenobiotic metabolism, each consisting of proteins that 
share >40% amino acid sequence homology. Each 
family contains subfamilies of proteins (designated by 
capital letters) that share >60% amino acid sequence 
homology. This nomenclature replaces other classifi- 
cations that often designated P-450s by substrate 
specificity or by response to known inducers. The 
enzymes demonstrated to be induced in the hepatocytes 
by Dim et al. (P-45OIA1 and P-450IA2) are “aryl 
hydrocarbon hydroxylases” and correspond to what has 
also been termed “P-448.” 
198 HEPATO1,OGY Elsewhere HEPATOLOGY 
The safety concern raised by the findings of Diaz et al. 
is new and not at all related to previous concerns about 
omeprazole directly causing mutagenesis (5) or predis- 
posing rats to carcinoid tumors. Rather, concern stems 
from the fact that P-450IA enzymes are responsible for 
the bioactivation of some aryl hydrocarbons to carcin- 
ogens. “Aryl’’ or “aromatic” refers to a broad class of 
hydrocarbons that contain benzenelike carbon rings in 
their structures. These chemicals are found in cigarette 
smoke, charbroiled food and industrial solvents. If 
omeprazole is an inducer of P-45OIA enzymes, 
treatment with the drug might theoretically predispose 
individuals to bioactivate otherwise harmless procar- 
cinogens in the environment, possibly resulting in 
malignancies many years after starting therapy. The 
studies performed by Diaz et al. are complete and very 
carefully executed. However, we believe that the data 
presented and the current state of knowledge about the 
role of P-450s in disease are insufficient to make 
conclusions regarding the safety of omeprazole in 
patients. We would like to make several points in this 
regard. 
First, although there can be no doubt that 
omeprazole-induced P-45OIA2 and probably P-45OIA1 
in the hepatocytes, the relevance of these findings to 
patients treated with omeprazole is less clear. P-450IA1 
appears to be primarily an extrahepatic enzyme in man 
and is usually present in the liver at concentrations 
below limits of detection by most assays (2, 3). The 
apparent prominence of P-450IA1 mRNA and catalytic 
activity observed by Diaz et al. in the omeprazole-treated 
hepatocytes may therefore indicate nonphysiological 
regulation of P-450IA enzymes in the culture system. 
Second, although the results of the in vivo biopsy 
studies appear to validate the authors’ in vitro findings, 
they run contrary to a t  least one clinical observation. 
Omeprazole treatment does not appear to significantly 
accelerate clearance of theophylline (6), although P- 
450IA2 catalyzes a major metabolic pathway ( N -  
demethylation [71) for this drug. The in vivo changes in 
P-450IA protein and catalytic activity observed by Diaz 
et al. were generally small compared with that observed 
in culture and may not have resulted from the ome- 
prazole treatment. It seems likely that patient medica- 
tions and diets changed significantly between the first 
and second biopsies. Moreover, variations in P-45OIA2 
protein concentration of less than twofold (observed in 
three of the 5 patients studied) could merely reflect 
differences in biopsy site because the distributions of 
these enzymes do not appear to be uniform in the livers 
of rats or man (8). 
Third, the relationship between P-450IA enzymatic 
activity and aryl hydrocarbon-asssociated carcino- 
genesis is indirect and best associated with P-45OIA1 
activity in extrahepatic tissues (9). In vitro assays for 
mutagenesis or DNA adduct formation indicate that 
aryl hydrocarbon procarcinogens are bioactivated by 
P-450IA enzymes. In animals, administration of very 
large doses of aryl hydrocarbons is associated with the 
development of lung, brain and lymphoreticular tumors. 
In some studies, patients with lung cancer have had 
higher levels of lymphocyte aryl hydrocarbon hydrox- 
ylase activity compared with patients without lung 
cancer. Collectively, these studies suggest a relationship 
between P-45OIA levels and chemical-induced carcino- 
genesis; however, a true causal relationship remains to 
be defined. As the authors point out, there is reason to 
believe that induction of P-450IA enzymes may in fact be 
protective against some induced malignancies. 
Fourth, it is probably not appropriate to single out 
inducers of P-450IA enzymes as a safety concern. 
Activation of procarcinogens is also catalyzed by P- 
450IIE1 (nitrosamines), P-450IIIA (mycotoxins) and 
probably many other P-450s (2, 3). Moreover, modifi- 
cation in the “profile” of liver P-450 activity is an 
expected part of many and perhaps most medication 
regimens. Although omeprazole is the first drug iden- 
tified as a potential inducer of P-450IA, medications that 
induce P-450IIE1 (ethanol and isoniazid) and P-450IIIA 
(rifampicin, antiseizure medications, glucocorticoids) 
are widely used (2, 3). In addition, any drug that is 
metabolized by- and hence binds to - a P-450 (which 
appears to be most drugs) will likely inhibit the activity 
of that P-450 toward other substrates (2). Inhibiting a 
pathway involved in detoxification could theoretically 
“shunt” xenobiotics through bioactivation pathways, 
resulting in the same net health consequences as a P-450 
inducer. 
Finally, even if omeprazole treatment does result in 
a two- to eightfold induction of hepatic P-45OIA en- 
zymes in patients, this would intuitively seem to be 
unimportant in most patients. There appears to be 
great heterogeneity in the expression of P-450IA en- 
zymes in man; several studies suggest a 30- to 60-fold 
interpatient variation in the liver content and catalytic 
activity of hepatic P-45OIA enzymes (2, 3). After a two- 
to eightfold induction, most patients would probably 
still remain within 2 S.D. of the mean in this broad 
distribution. 
We eagerly await studies that document the health 
risks or benefits associated with the wide interpatient 
variations in activities of the P-450s that appear to exist 
independent of the influence of medications. The con- 
tinued development of noninvasive assays capable of 
determining activities of individual P-450s (2) will allow 
such prospective long-term studies. In the meantime, it 
would seem inappropriate to deny omeprazole to pa- 
tients whose symptoms have been refractory to other 
available medications, even if omeprazole is confirmed to 
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CORTICOSTEROIDS AND ALCOHOLIC HEPATITIS 
Imperiale TF, McCullough AJ. Do corticosteroids 
reduce mortality from alcoholic hepatitis. Ann Intern 
Med 1990;113:299-307. 
EDITOR’S ABSTRACT 
The purpose of the study was to determine whether 
corticosteroids affect short-term mortality from alco- 
holic hepatitis. A metanalysis was conducted using 
studies identified through a MEDLINE computer 
search from 1966 to 1989 and extensive manual 
searches of associated bibliographies. Eleven ran- 
domized studies that assessed mortality in hospitalized 
patients diagnosed with alcoholic hepatitis and 
treated with corticosteroids were evaluated. Overall, 
the protective efficacy of corticosteroids was 3770 (95% 
confidence interval 20% to 50%). Protective efficacy 
was higher among those trials with higher quality 
scores and in trials that excluded subjects with active 
gastrointestinal bleeding in patients with hepatic en- 
cephalopathy, protective efficacy was 34% overall (con- 
fidence interval 15% to 48%). In subjects without 
hepatic encephalopathy, corticosteroids were not be- 
lieved to have a protective effect; this lack of efficacy 
was noted across all trial subgroups. Results of the 
metanalysis suggest that corticosteroids reduce short- 
term mortality in patients with acute alcoholic hepa- 
titis who have hepatic encephalopathy. The protective 
effect is dependent on exclusion of patients with acute 
gastrointestinal bleeding. 
COMMENTS 
This important metanalysis responds, a t  least tempo- 
rally, to an editorial published in the same journal 
almost a year earlier calling for a metanalysis of the 
benefit of corticosteroids in the treatment of alcoholic 
hepatitis (1). The most widely accepted therapy for acute 
alcoholic hepatitis is general supportive care. Research 
into the mechanism of liver injury from alcohol has lead 
to the treatment of alcoholic hepatitis with a number of 
agents, including propylthiouracil, anabolic steroids and 
corticosteroids. The latter has been the most intensively 
studied, starting with a report in 1971 of a randomized 
controlled study terminated early by the investigators 
because of the overwhelming protective effect found for 
corticosteroid use in encephalopathic patients with 
alcoholic hepatitis (2). A succession of randomized 
controlled trials followed, two of which showed sig- 
nificant improvement in survival with steroids and 
seven of which did not. In 1989 a multicenter trial found 
a substantial benefit from steroid treatment in a 
population of patients selected for encephalopathy or 
high prothrombin times and bilirubin levels (3). 
Combining results from multiple trials allows a 
metanalysis to achieve large sample sizes and statisti- 
cally significant results where individual trials have 
failed to do so. Accumulating a large sample size in this 
manner is easy relative to the difficulty of conducting a 
large clinical trial. However, to prevent the sample size 
from giving the reader false confidence in the results of 
the analysis, the methodology of the metanalysis as- 
sumes an even greater significance for both authors and 
readers. Imperiale and McCullough carefully follow the 
emerging standards for the performance of a met- 
analysis by specifying the literature-search methods, 
supplying a list of rejected trials, describing the criteria 
for the quality review of the articles and describing 
standards for deciding if the trials may be appropriately 
aggregated. 
Although the authors adhere to many of the standards 
of metanalysis methodology, in a few areas their meth- 
odology could be more rigorously described. It is very 
important for a metanalysis to use all available studies 
done on the research question. Imperiale and McCul- 
lough describe their use of a computerized database, 
textbook references and references from the articles 
retrieved by the first two methods. A more complete 
search would have specified the use of a professional 
librarian to perform the computer search, as skill in 
using these databases varies widely. Other sources for 
finding references recommended in the literature on 
metanalysis include Current Contents, databases of 
unpublished material and polls of senior researchers in 
the field (4). The latter two sources are important for 
addressing the issue of publication bias or the selective 
appearance in the published literature of trials with 
positive results. The authors’ case for the lack of 
publication bias, on the grounds that a large proportion 
of the studies found no significant difference in the 
study groups, is not compelling. Although the question 
of how to include unpublished studies in a pooled 
analysis is complicated, a simple sensitivity analysis can 
be done to determine how many unpublished negative 
trials (of good quality) would be required to render the 
result of the pooled analysis statistically insignificant. 
